HNGEHealthcare · Health Information ServicesThe 17 Wall Street analysts covering Hinge Health, Inc. hold a median 12-month price target of $135 — +11.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Hinge Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (97): Analysts have, on balance, been raising their forecasts.
Volatility (30): The share price moves around a lot.
Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on HNGE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +11.7% from it.
Of the 20 most recent actions, 15 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Nov 2026 | Canaccord Genuity | Maintains | Buy | $105 → $134 |
| 3 Nov 2026 | Evercore ISI Group | Maintains | Outperform | $125 → $150 |
| 3 Nov 2026 | Freedom Capital Markets | Maintains | Buy | $103 → $135 |
| 3 Nov 2026 | Morgan Stanley | Maintains | Overweight | $117 → $131 |
| 3 Nov 2026 | Needham | Maintains | Buy | $115 → $135 |
| 3 Nov 2026 | RBC Capital | Maintains | Outperform | $110 → $135 |
| 3 Nov 2026 | Stifel | Maintains | Buy | $130 → $135 |
| 3 Nov 2026 | Truist Securities | Maintains | Buy | $112 → $145 |
| 3 Nov 2026 | Wells Fargo | Maintains | Overweight | $103 → $132 |
| 26 Oct 2026 | Stifel | Maintains | Buy | $115 → $130 |
| 16 Oct 2026 | Keybanc | Maintains | Overweight | $125 → $140 |
| 16 Oct 2026 | Keybanc | Maintains | Overweight | — |
| 12 Oct 2026 | Barclays | Maintains | Overweight | $100 → $110 |
| 12 Oct 2026 | Barclays | Maintains | Overweight | — |
| 30 Sept 2026 | Needham | Maintains | Buy | $97 → $115 |
| 30 Sept 2026 | Needham | Maintains | Buy | — |
| 22 Sept 2026 | Baird | Maintains | Neutral | — |
| 22 Sept 2026 | Baird | Maintains | Neutral | $85 → $90 |
| 8 Sept 2026 | Stifel | Maintains | Buy | $96 → $115 |
| 8 Sept 2026 | Stifel | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
HNGE appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Hinge Health, Inc. returned +126.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 23% of US stocks
Cheaper than 12% of US stocks
Cheaper than 3% of US stocks
Cheaper than 4% of US stocks
Higher than 86% of US stocks
Higher than 76% of US stocks
Higher than 95% of US stocks
Higher than 82% of US stocks
Higher than 83% of US stocks
Higher than 93% of US stocks
Higher than 94% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Hinge Health, Inc. has a market value of $9.4B and an enterprise value of $9.2B.
Revenue in the twelve months to 30 June 2026: $720.1M. The latest quarter grew 52.4% year on year.
Net income over the same four quarters: $109.1M, a 15.1% net margin.
Diluted earnings per share, trailing twelve months: $1.28.
Free cash flow in the twelve months to 30 June 2026: $283.9M, after $6.2M of capital spending.
Trailing P/E: 32.5×; forward P/E: 36.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Hinge Health, Inc. employs 1,437 people — $501K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Hinge Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Hinge Health, Inc.’s Q3 2026 earnings call. The excerpt provides no details about the discussion.
Why it matters — HNGE watchers may use the transcript to review management’s remarks, but the provided text contains no specific business or financial updates.
Hinge Health reported third-quarter revenue growth of 52% year over year and raised its full-year outlook. The company cited higher member engagement, client additions and improved operating leverage.
Why it matters — HNGE watchers may note the reported growth and higher outlook alongside the factors the company identified as supporting performance.
Hinge Health reported quarterly earnings of $0.71 per share, above the Zacks Consensus Estimate of $0.63. Earnings were $0.34 per share in the year-ago quarter.
Why it matters — HNGE watchers may note the company exceeded the cited earnings estimate and reported higher per-share earnings than a year ago.
Hinge Health announced financial results for the third quarter ended September 30, 2026, and provided a business update. CEO Daniel Perez said the company’s performance reflects its focus on clinical outcomes, healthcare experience, and lower client costs.
Why it matters — The update gives HNGE watchers the company’s account of its quarterly performance and stated operating priorities.
The article highlights Hinge Health’s strong revenue growth, raised 2026 outlook, and expansion into Migraine and GI care, while noting investment pressures.
Why it matters — These factors give HNGE watchers context on the company’s growth prospects and the costs accompanying its expansion.
The 17 Wall Street analysts covering Hinge Health, Inc. have a median 12-month price target of $135, with estimates ranging from $90 to $151. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Hinge Health, Inc., 16 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Hinge Health, Inc. 86 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Hinge Health, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +11.7% from the last close, and Ticker Nerd's factor model ranks Hinge Health, Inc. 86 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Hinge Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HNGE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $90 to $151 over the next 12 months.
Hinge Health, Inc. returned +126.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Hinge Health, Inc. Class A Common Stock represents ownership in Hinge Health, a digital healthcare company focused on musculoskeletal care.
The most recent item we track (Seeking Alpha, 3 Nov 2026): "Hinge Health, Inc. (HNGE) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Hinge Health, Inc.’s Q3 2026 earnings call. The excerpt provides no details about the discussion.
Hinge Health, Inc. Class A Common Stock represents ownership in Hinge Health, a digital healthcare company focused on musculoskeletal care. The company provides software-driven solutions for joint and muscle health, combining virtual care, clinician support, and digital programs designed to help people manage acute injury, chronic pain, and recovery from surgery. Its platform is used by employers, health plans, and other healthcare payers seeking scalable care delivery for members with MSK needs. Hinge Health also incorporates technologies such as artificial intelligence, motion tracking, and connected wearable devices to support personalized care experiences. Based in San Francisco, Hinge Health serves a specialized segment of the healthcare technology market centered on prevention, treatment, and management of musculoskeletal conditions.
CEO Mr. Daniel A. Perez · 1,437 employees · United States · https://www.hingehealth.com
